Category Archives: Parkinson’s Treatment

Parkinsons Disease Treatment Market Report Coverage: Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast. A recent market research report added to repository of Credible Markets is an in-depth analysis of Global Parkinsons Disease Treatment Market. On the basis of historic growth analysis and current scenario of Parkinsons Disease Treatment market place, the report intends to offer actionable insights on global market growth projections Continue reading →

DUBLIN--(BUSINESS WIRE)--The "Parkinson's - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering. "Parkinson's: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Parkinson's disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Parkinson's , drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2026. Epidemiology Forecasts to 2026: This section of the report provides the overview of Parkinson's diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2018 till 2026 Continue reading →

December 10, 2020 07:00 ET | Source: Newscope Capital Corporation TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- PharmaTher Inc., (PharmaTher or the Company), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has been granted a Pre-Investigational New Drug (PIND) meeting with the U.S. Food and Drug Administration (FDA) for the clinical development of ketamine in Parkinsons disease and its proposed Phase 2 clinical study for ketamine in the treatment of levodopa-induced dyskinesia associated with Parkinsons disease (LID-PD) Continue reading →

The most critical problem in the treatment of neurodegenerative diseases is brain neuronal protection, which can be overcome by clearing pathological substances and regulating the immune environment. In the above treatment strategies, the traditional poor drug delivery problem is inevitable. Here, we show an engineering core-shell hybrid system named rabies virus glycoprotein (RVG) peptidemodified exosome (EXO) curcumin/phenylboronic acid-poly(2-(dimethylamino)ethyl acrylate) nanoparticle/small interfering RNA targeting SNCA (REXO-C/ANP/S) Continue reading →

Rare Brain Diseases Linked to COVID-19 Fuel Demand for Neural Implants As the number of COVID-19 (coronavirus) cases continue to rise in the U.S., Russia, France, and Brazil, life-threatening and rare brain diseases are being linked to the infection. This has brought companies in the brain implants market into picture, since their assistance is crucial in the already stressed healthcare facilities. It has been found that certain individuals in their late 50s are at a risk of developing acute necrotizing encephalitis, which is a rare complication of influenza and other viral infections. Continue reading →

Anosmia is the inability or decreased ability to smell. It can be permanent or temporary, depending on the cause Continue reading →

NEW YORK, Dec. Continue reading →

RESULTS Histone H3K4me3 and its catalyzing enzymes are significantly elevated in PFC of patients with AD and mutant Tau transgenic mice To elucidate the role of histone methylation in AD, we examined the alterations of histone methylation marks associated with gene activation or silencing in the postmortem PFC (Brodmanns area 10) tissues from patients with AD (five to six Braak stages). Compared with age- or sex-matched control subjects, the level of permissive H3K4me3 in the nuclear fraction of PFC lysates from patients with AD was significantly increased [Fig. 1A; Ctrl: n = 9, AD: n = 11, t(18) = 5.4, P < 0.001; t test], while no significant changes were found on the level of repressive H3K27me3 or enhancer H3K4me Continue reading →

BELLEAIR The Town Commission may install a temporary replacement for Mayor Gary H. Continue reading →

December 08, 2020 07:00 ET | Source: Cerevel Therapeutics CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an independent member of its Board of Directors. Dr. Continue reading →